← Back to Clinical Trials
Recruiting NCT06208137
Using the Composite Immune Risk Score to Assess and Modulate the Patient's Post-transplant Immune Reconstitution.
Trial Parameters
Condition Transplant-Related Disorder
Sponsor Institute of Hematology & Blood Diseases Hospital, China
Study Type INTERVENTIONAL
Phase N/A
Enrollment 456
Sex ALL
Min Age 16 Years
Max Age N/A
Start Date 2024-02-29
Completion 2027-10-01
Interventions
Health monitoring and regular return follow-up reminders
Brief Summary
To assess the effectiveness of interventions including health monitoring and regular return follow-up reminders for patients with a high Composite Immune Risk Score.
Eligibility Criteria
Inclusion Criteria: * 1\) Patients must be ≥ 16 years of age; * 2\) Patients receiving haploidentical allo-HSCT; * 3\) Patients have to sign an informed consent form before the start of the research procedure. Exclusion Criteria: * 1\) Tandem transplantation or multiple transplantations; * 2\) Mental or other medical conditions that make the patients unable to comply with the research treatment and monitoring requirements; * 3\) Patients who are ineligible for the study due to other factors, or will bear great risk if participating in the study.